Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jan;67(1):10–14. doi: 10.1038/bjc.1993.3

2 chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms.

R A Nagourney 1, S S Evans 1, J C Messenger 1, Y Z Su 1, L M Weisenthal 1
PMCID: PMC1968239  PMID: 8094002

Abstract

2-Chlorodeoxyadenosine (2-CDA) is an adenosine deaminase resistant analogue of deoxyadenosine which has shown clinical activity in human hematologic neoplasms. The exact mode of action of this drug remains the subject of investigation. We applied the Differential Staining Cytotoxicity (DiSC) assay to 50 human tumour specimens obtained from patients with a variety of hematologic malignancies to characterise the activity spectrum of 2-CDA. We evaluated the disease-specific activity of this agent in vitro and compared its relative cytotoxicity with that of other antineoplastic agents in current clinical use. Comparisons were conducted against nitrogen mustard, doxorubicin, vincristine and cytosine arabinoside. Our results indicate that 2-CDA has activity in myeloid and many lymphoid neoplasms but that multiple myeloma specimens reveal significant resistance. Cross resistance studies reveal a correlation between 2-CDA and the alkylator nitrogen mustard but no correlation between 2-CDA and doxorubicin, vincristine nor cytosine arabinoside. The results suggest 2-CDA activity in many human hematologic neoplasms with the clear exception of multiple myeloma and further suggest a relationship between this agent and alkylators of the mustard class. The DiSC assay may provide useful insights in the pre-clinical evaluation of new antineoplastic drugs and may help to elucidate drug activities and mechanisms of action.

Full text

PDF
10

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Avery T. L., Rehg J. E., Lumm W. C., Harwood F. C., Santana V. M., Blakley R. L. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice. Cancer Res. 1989 Sep 15;49(18):4972–4978. [PubMed] [Google Scholar]
  2. Berger N. A. Poly(ADP-ribose) in the cellular response to DNA damage. Radiat Res. 1985 Jan;101(1):4–15. [PubMed] [Google Scholar]
  3. Berger N. A., Sikorski G. W., Petzold S. J., Kurohara K. K. Association of poly(adenosine diphosphoribose) synthesis with DNA damage and repair in normal human lymphocytes. J Clin Invest. 1979 Jun;63(6):1164–1171. doi: 10.1172/JCI109410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bird M. C., Bosanquet A. G., Forskitt S., Gilby E. D. Semi-micro adaptation of a 4-day differential staining cytotoxicity (DiSC) assay for determining the in-vitro chemosensitivity of haematological malignancies. Leuk Res. 1986;10(4):445–449. doi: 10.1016/0145-2126(86)90075-5. [DOI] [PubMed] [Google Scholar]
  5. Bosanquet A. G. Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay. Lancet. 1991 Mar 23;337(8743):711–714. doi: 10.1016/0140-6736(91)90287-y. [DOI] [PubMed] [Google Scholar]
  6. Bosanquet A. G. Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents. Cancer Chemother Pharmacol. 1985;14(2):83–95. doi: 10.1007/BF00434343. [DOI] [PubMed] [Google Scholar]
  7. Carrera C. J., Terai C., Lotz M., Curd J. G., Piro L. D., Beutler E., Carson D. A. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. J Clin Invest. 1990 Nov;86(5):1480–1488. doi: 10.1172/JCI114865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Carrera C. J., Yamanaka H., Piro L. D., Lotz M., Carson D. A. Profound toxicity of deoxyadenosine and 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. Adv Exp Med Biol. 1989;253B:219–225. doi: 10.1007/978-1-4684-5676-9_33. [DOI] [PubMed] [Google Scholar]
  9. Carson D. A., Wasson D. B., Beutler E. Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine. Proc Natl Acad Sci U S A. 1984 Apr;81(7):2232–2236. doi: 10.1073/pnas.81.7.2232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Carson D. A., Wasson D. B., Kaye J., Ullman B., Martin D. W., Jr, Robins R. K., Montgomery J. A. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A. 1980 Nov;77(11):6865–6869. doi: 10.1073/pnas.77.11.6865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Carson D. A., Wasson D. B., Taetle R., Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 1983 Oct;62(4):737–743. [PubMed] [Google Scholar]
  12. Gazdar A. F., Steinberg S. M., Russell E. K., Linnoila R. I., Oie H. K., Ghosh B. C., Cotelingam J. D., Johnson B. E., Minna J. D., Ihde D. C. Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J Natl Cancer Inst. 1990 Jan 17;82(2):117–124. doi: 10.1093/jnci/82.2.117. [DOI] [PubMed] [Google Scholar]
  13. Griffig J., Koob R., Blakley R. L. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res. 1989 Dec 15;49(24 Pt 1):6923–6928. [PubMed] [Google Scholar]
  14. Hentosh P., Koob R., Blakley R. L. Incorporation of 2-halogeno-2'-deoxyadenosine 5-triphosphates into DNA during replication by human polymerases alpha and beta. J Biol Chem. 1990 Mar 5;265(7):4033–4040. [PubMed] [Google Scholar]
  15. Kay A. C., Saven A., Carrera C. J., Carson D. A., Thurston D., Beutler E., Piro L. D. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol. 1992 Mar;10(3):371–377. doi: 10.1200/JCO.1992.10.3.371. [DOI] [PubMed] [Google Scholar]
  16. Lathan B., von Tettau M., Verpoort K., Diehl V. Pretherapeutic drug testing in acute leukemias for prediction of individual prognosis. Haematol Blood Transfus. 1990;33:295–298. doi: 10.1007/978-3-642-74643-7_53. [DOI] [PubMed] [Google Scholar]
  17. Pemble L. B., Lihou M. G., Blakley R. L., Jamieson G. P., Smith P. J. Lack of cross-resistance between cytosine arabinoside and a new halogenated nucleoside analogue, 2-bromo-2'-deoxyadenosine in human acute myeloid leukaemia cells. Cancer Chemother Pharmacol. 1987;20(2):155–161. doi: 10.1007/BF00253971. [DOI] [PubMed] [Google Scholar]
  18. Piro L. D., Carrera C. J., Beutler E., Carson D. A. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood. 1988 Sep;72(3):1069–1073. [PubMed] [Google Scholar]
  19. Piro L. D., Carrera C. J., Carson D. A., Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990 Apr 19;322(16):1117–1121. doi: 10.1056/NEJM199004193221605. [DOI] [PubMed] [Google Scholar]
  20. Santana V. M., Mirro J., Jr, Harwood F. C., Cherrie J., Schell M., Kalwinsky D., Blakley R. L. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol. 1991 Mar;9(3):416–422. doi: 10.1200/JCO.1991.9.3.416. [DOI] [PubMed] [Google Scholar]
  21. Santana V. M., Mirro J., Jr, Kearns C., Schell M. J., Crom W., Blakley R. L. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol. 1992 Mar;10(3):364–370. doi: 10.1200/JCO.1992.10.3.364. [DOI] [PubMed] [Google Scholar]
  22. Seto S., Carrera C. J., Kubota M., Wasson D. B., Carson D. A. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest. 1985 Feb;75(2):377–383. doi: 10.1172/JCI111710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Smulson M. E., Schein P., Mullins D. W., Jr, Sudhakar S. A putative role for nicotinamide adenine dinucleotide-promoted nuclear protein modification in the antitumor activity of N-methyl-N-nitrosourea. Cancer Res. 1977 Sep;37(9):3006–3012. [PubMed] [Google Scholar]
  24. Tanabe K., Hiraoka W., Kuwabara M., Sato F., Matsuda A., Ueda T. Induction of DNA double-strand breaks in Chinese hamster V79 cells by 2-chlorodeoxyadenosine. Chem Biol Interact. 1989;71(2-3):167–175. doi: 10.1016/0009-2797(89)90032-x. [DOI] [PubMed] [Google Scholar]
  25. Tidefelt U., Sundman-Engberg B., Rhedin A. S., Paul C. In vitro drug testing in patients with acute leukemia with incubations mimicking in vivo intracellular drug concentrations. Eur J Haematol. 1989 Nov;43(5):374–384. doi: 10.1111/j.1600-0609.1989.tb00323.x. [DOI] [PubMed] [Google Scholar]
  26. Weisenthal L. M., Marsden J. A., Dill P. L., Macaluso C. K. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res. 1983 Feb;43(2):749–757. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES